Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8737635 | Human Immunology | 2018 | 17 Pages |
Abstract
Transplantation is currently the therapy of choice for endstage organ failure even though it requires long-term immunosuppresive therapy, with its numerous side effects, for acceptance of the transplanted organ. In rare cases however, patients develop operational tolerance, that is, graft survival without immunosuppression. Studies conducted on these patients reveal genetic, phenotypic, and functional signatures. They provide a better understanding of the immunological mechanisms involved in operational tolerance and define biomarkers that could be used to adapt immunosuppressive treatment to the individual, safely reduce immunosuppression doses, and ideally and safely guide immunosuppression withdrawal. This review summarizes studies that suggest a role for B cells as biomarkers of operational tolerance and discusses the use of B cells as a predictive tool for immunologic risk.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
M. Chesneau, R. Danger, J.-P. Soulillou, S. Brouard,